Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CIKN/A
WebN/A
Phone(310) 655-2928
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions
What is Armata Pharmaceuticals' stock symbol?
Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."
How were Armata Pharmaceuticals' earnings last quarter?
Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) issued its earnings results on Wednesday, August, 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.40. View Armata Pharmaceuticals' Earnings History.
When is Armata Pharmaceuticals' next earnings date?
What price target have analysts set for ARMP?
2 brokers have issued 1 year price targets for Armata Pharmaceuticals' stock. Their forecasts range from $7.00 to $9.00. On average, they expect Armata Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 97.5% from the stock's current price. View Analyst Price Targets for Armata Pharmaceuticals.
What is the consensus analysts' recommendation for Armata Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Armata Pharmaceuticals.
What are Wall Street analysts saying about Armata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Armata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (8/19/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019)
Has Armata Pharmaceuticals been receiving favorable news coverage?
News coverage about ARMP stock has trended very negative recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Armata Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Armata Pharmaceuticals.
Are investors shorting Armata Pharmaceuticals?
Armata Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totalling 161,900 shares, a decline of 9.0% from the August 15th total of 177,900 shares. Based on an average daily trading volume, of 17,900 shares, the days-to-cover ratio is currently 9.0 days. Currently, 3.7% of the shares of the company are sold short. View Armata Pharmaceuticals' Current Options Chain.
Who are some of Armata Pharmaceuticals' key competitors?
Some companies that are related to Armata Pharmaceuticals include MediGene (MDG1), Cynata Therapeutics (CYP), CorMedix (CRMD), Ergomed (ERGO), Lineage Cell Therapeutics (LCTX), IMV (IMV), Verseon (VSN), CorMedix (CRMD), Fennec Pharmaceuticals (FRX), Burcon NutraScience (BU), Matinas BioPharma (MTNB), Antibe Therapeutics (ATE), Sirona Biochem (SBM), Medlab Clinical (MDC) and Immutep (IMM).
What other stocks do shareholders of Armata Pharmaceuticals own?
Who are Armata Pharmaceuticals' key executives?
Armata Pharmaceuticals' management team includes the folowing people:
- Todd R. Patrick, Chief Executive Officer & Director
- Brian C. Varnum, President & Chief Development Officer
- Duane A. Morris, Vice President-Operations
- Steven Robert Martin, Chief Financial Officer & Head-Media Contacts
How do I buy shares of Armata Pharmaceuticals?
Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Armata Pharmaceuticals' stock price today?
One share of ARMP stock can currently be purchased for approximately $4.05.
How big of a company is Armata Pharmaceuticals?
How can I contact Armata Pharmaceuticals?
The company can be reached via phone at (310) 655-2928.
MarketBeat Community Rating for Armata Pharmaceuticals (NYSEAMERICAN ARMP)
MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
